Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Peter Goldschmidt
|
| gptkbp:country |
gptkb:Germany
|
| gptkbp:focus |
consumer healthcare products
generics specialty pharmaceuticals |
| gptkbp:founded |
1895
|
| gptkbp:headquarters_location |
gptkb:Bad_Vilbel
|
| https://www.w3.org/2000/01/rdf-schema#label |
STADA Arzneimittel
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
DE0007251803
|
| gptkbp:legalForm |
gptkb:company
|
| gptkbp:market |
global
|
| gptkbp:notableBrand |
Aqualibra
Grippostad Ladival Mobilat Snup Zoflora |
| gptkbp:numberOfEmployees |
~12,300
|
| gptkbp:parentOrganization |
gptkb:Cinven
gptkb:Bain_Capital |
| gptkbp:products |
generic drugs
over-the-counter drugs |
| gptkbp:revenue |
~€3 billion (2022)
|
| gptkbp:stockExchange |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:stockSymbol |
SAZ
|
| gptkbp:website |
https://www.stada.com/
|
| gptkbp:bfsParent |
gptkb:Natur_Produkt
gptkb:epoetin_zeta |
| gptkbp:bfsLayer |
7
|